All News

Metanalysis of 33 clinical trials show that corticosteroids are anaglesic, especially in 1st 3 mos (mean drop VAS pain -12mm); after that benefit wanes to -8mm @3-6 mos and -6mm (95% CI, -10mm, -2mm) after  6 mos. https://t.co/IKZhqqwhPO

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

d Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
knee.injx_.lat_.jpg

ICYMI: EULAR Guidelines on Intraarticular Therapy

d Jack Cush, MD

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

d Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
lupus.jpg

How Do You Measure Success When It Comes to SLE?

d Kathryn H. Dao, M.D.

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

RA after 70: Too Old for bioDMARDs?

d Aurelie Najm, MD, PhD

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.

Read Article
#EULAR2021 POS0105: Predictors of flare in SLE low disease activity state: ⭐️Ongoing glucocorticoid treatment ⭐️Ongoing immunosuppressant treatment ⭐️Anti-RNP antibody @RheumNow

Eric Dein ejdein1 ( View Tweet)

Rheum alliance trainee survey (n=302): 87-96% report negative impact of COVID19 on Rheumatology training: -outpatient clinics (79%) -inpatient consultations (59%) -formal teaching (55%) -procedures (53%) and -ultrasonography (36%) #POS0051 @RheumNow #EULAR2021 @kristenyoung

Aurelie Najm AurelieRheumo ( View Tweet)

Very informative #EULAR2021 WIN session on MIS-C @EULAR_org 👉 Steroids early 👉 IVIg in all 👉 anticoagulant use remains variable #Coronary aneurysms ✅ occur during acute phase in MIS-C and improve with treatment ✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD AshimaMakol ( View Tweet)
Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

Eric Dein ejdein1 ( View Tweet)

Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference

k dao KDAO2011 ( View Tweet)

Our meta-analysis on IA GC effects on pain and function in knee OA vs. controls at different time points: short term superiority of IA GC, medium term effect is no longer significant apart vs PBO and long term IA GC non superior vs controls. #EULAR2021 @RheumNow #POS1099 https://t.co/mQ0bMF03IT
Aurelie Najm AurelieRheumo ( View Tweet)
Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

🚨So after LoVAS Now this Ritux + MMF + Pulse MPS No oral steroids 🤯 @ARD_BMJ @EBRheum - Lesser is better ?? https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS

Links:

EnvisionRheumat ERheumat ( View Tweet)
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow

Eric Dein ejdein1 ( View Tweet)

I'm presenting data on COVID-19 in Irish rheumatic disease patients. Age, number comorbidities, glucocorticoids, associated increased hospitalisation. Inflammatory arthritis associated decreased hospitalisation. @RheumNow #EULAR2021 #AbstrPOS1162 https://t.co/0gKxiMNYTf
Richard Conway RichardPAConway ( View Tweet)
gout podagra inflammed

Best Interventions for Gout Flares

d Jack Cush, MD

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].

Read Article
RheumNow Podcast square

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
knee.surgery.jpg (keep)

Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections

d Jack Cush, MD

The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.